Insertion of human interleukin-15 into pJET vector for anti-cancer vaccine development

Cancer is claimed to be the first killer for human beings nowadays. Tumours have high capability to escape from host immune responses, thus currently there are still no effective immunotherapeutic strategies that can be used to cure cancer. Today, cytokines are highly involving in cancer immunotherapy. The interleukin-15 (IL-15) possess several properties in cancer treatment including the regulation of natural killer (NK) cells activities and the triggering and stimulation of B- and T-lymphocytes proliferation. IL-15 appears to be a better option for treating cancer as it is less toxic when compared to IL-2. In order to develop an effective vaccine against cancer, the human IL-15 (hIL-15) gene was cloned as a cDNA and inserted into the pJET cloning vector. The recombinant plasmid was transformed into chemically competent Escherichia coli TOP10 cells and was analyzed by agarose gel electrophoresis. The restriction enzyme used for digestion of this recombinant plasmid was the NheI to confirm the presence of hIL-15 gene in the pJET vector. The hIL-15 gene was proven to be inserted into the pJET vector after digestion with NheI restriction enzyme which showed an insert size of 0.5 kb. The recombinant plasmid was sent for sequencing to determine the nucleotide sequence of the inserted gene. BLAST was performed and the result confirmed the 100% similarity of the sequence homology to the published hIL-15 gene. The recombinant plasmid could be used for further analysis for the development of anti-cancer vaccine.

Text FBSB 2015 116 - IR.pdf Download (1MB)

Actions (login required)

View Item